疫苗教育T细胞与CD123双特异性T细胞衔接器联合治疗急性髓系白血病
该研究在小鼠异种移植模型中探讨CD123双特异性T细胞衔接器(SAR440234)联合自体树突细胞/急性髓系白血病融合疫苗刺激的T细胞(veTcs)的疗效。体外实验显示联合治疗增强肿瘤特异性T细胞免疫和抗白血病效应;体内联合治疗完全根除白血病移植,优于SAR440234联合未教育T细胞。
要点
- CD123 TCE(SAR440234)联合veTcs在体外增强肿瘤特异性T细胞免疫和抗白血病效应。
- 体内联合治疗完全根除白血病移植,优于SAR440234联合未教育T细胞。
- 该效应与细胞毒性T细胞亚群增加和克隆性扩增相关。
核心结论
- TCE联合过继转移veTcs是一种新方法,值得在临床试验中进一步研究。
研究设计与样本
- 研究采用小鼠异种移植模型,探索靶向人CD123的TCE(SAR440234)联合自体树突细胞/急性髓系白血病融合疫苗刺激的T细胞(veTcs)。
主要发现
- 体外实验显示,CD123 TCE(SAR440234)联合veTcs增强肿瘤特异性T细胞免疫和抗白血病效应。
- 体内实验中,SAR440234联合veTcs完全根除白血病移植,优于SAR440234联合未教育T细胞。
- 该效应与细胞毒性T细胞亚群增加和克隆性扩增相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell engager (TCE) therapy has demonstrated significant therapeutic efficacy in patients with hematologic malignancies. Durable responses have been linked with T-cell clonotypic expansion. We hypothesized that combining vaccine-educated T cells (veTcs) that induce the expansion of leukemia-specific T cells would enhance efficacy of TCE through greater induction of tumor-specific immunity. In this study, we explored a TCE targeting human CD123 on myeloid leukemia cells in conjunction with T cells stimulated by an autologous dendritic cell/acute myeloid leukemia fusion vaccine in a murine xenograft model. We demonstrated that the combination of CD123 TCE (SAR440234) and veTcs boosted tumor-specific T-cell immunity and enhanced antileukemia effect in vitro. Furthermore, in vivo SAR440234 and veTca combination treatment fully eradicated leukemia engraftment outperforming SAR440234 in conjunction with uneducated T cells. This effect was associated with an increase in cytotoxic T-cell subsets and clonotypic expansion. Thus, the combination of TCE with adoptive T-cell transfer of veTcs is a novel approach that merits further investigation in clinical trials.
引用
- Liegel J, Stroopinsky D, Cheloni G, et al. Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia. Blood Adv. 2025. PMID: 40811786. doi:10.1182/bloodadvances.2024015449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。